Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 8404234 Fixed dosing of HER antibodies

Patent 8404234 was granted and assigned to Genentech on March, 2013 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Current Assignee

Genentech

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

84042340

Patent Inventor Names

David E. Allison0

Jian-Feng Lu0

Chee M. Ng0

Rene Bruno0

Date of Patent

March 26, 2013

Patent Application Number

122482230

Date Filed

October 9, 2008

Patent Citations Received

‌

US Patent 12128103 Adjuvant treatment of HER2-positive breast cancer

‌

US Patent 11654105 Subcutaneous HER2 antibody formulations

‌

US Patent 11655305 Treatment of metastatic breast cancer

‌

US Patent 11992529 Adjuvant treatment of HER2-positive breast cancer

‌

US Patent 12110341 Composition comprising antibody that binds to domain II of HER2 and acidic variants thereof

Patent Primary Examiner

‌

Laura B Goddard

Patent abstract

The present invention concerns fixed dosing of HER antibodies, such as Pertuzumab.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 8404234 Fixed dosing of HER antibodies

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API